The C-reactive protein (CRP) testing market is projected to register a CAGR of 1.8% during the forecast period.
According to the study published in Annals of Clinical Microbiology and Antimicrobials, titled, 'Plasma CRP level is positively associated with the severity of COVID-19' in May 2020, plasma CRP levels were found to be linked to the severity of COVID-19 pneumonia. The findings could help distinguish mild COVID-19 pneumonia patients from those with moderate to severe COVID-19 pneumonia. This could serve as an early warning sign of serious disease, allowing doctors to better stratify patients for transfer to an intensive care unit. The importance of CRP testing in the COVID-19 infection for the stratification of patients will lead to increased demand for CRP testing, thereby impacting the market growth during the pandemic.
The major factors propelling the growth of the C-reactive protein testing market include the rise in prevalence of inflammatory disorders, diabetes, and cancers, the increasing global incidence of endometriosis in women, the rise in funding for the technological advancement in diagnostics, and the rise in the adoption of point-of-care devices.
According to the World Health Organization, cardiovascular diseases claimed the lives of 17.9 million individuals worldwide in 2019, accounting for 32% of all deaths. Heart attacks and strokes were responsible for 85 percent of these deaths. The rising prevalence of cardiovascular diseases will lead to increased adoption of CRP testing to identify the risk of cardiovascular disease, thereby expected to drive the market growth.
Furthermore, the rise in product launches of point-of-care CRP tests is expected to contribute to the growth of the CRP testing market. For instance, in May 2020, ProciseDx filed a 510k for the Procise CRP test. The test is performed utilizing ProciseDx's FRET (Fluorescent Resonance Energy Transfer) Point of Care equipment, which is an inflammatory marker extensively used in gastrointestinal therapy. This will lead to increased adoption of the point of care CRP test, thereby expected to drive the growth of the market.
Therefore, the rising prevalence of cardiovascular disease, and rising product launches for point-of-care CRP testing, among others, are expected to drive the growth of this market over the forecast period. On the other hand, lack of public awareness and availability of alternative treatments are the factors that are expected to hinder market growth.
The Enzyme-linked Immunosorbent Assay (ELISA) segment is expected to hold a significant share in the C-reactive protein testing market. The factors such as rise in prevalence of cancers, rise in infections such as COVID-19, rise in partnership for the commercialization of ELISA tests, and rise in product launches, among others, are expected to drive the growth of this segment during the forecast period.
According to Globocan 2020, the global cancer burden has risen to 19.3 million cases and 10 million cancer deaths in 2020. As the ELISA test can be a useful technique for detecting cancer markers, there will be increased adoption of this test for the detection of cancer across the world, thereby expected to drive the growth of this segment.
Furthermore, rising product launches of ELISA testing kits are also expected to propel this segment growth. For instance, in June 2021, J Mitra and Co Pvt Ltd, an Indian Invitro Diagnostics company, released the Covid-19 Ag Microlisa Elisa Test kit, often known as the Elisa Antigen Test to fight against Covid-19 by reducing the overall cost of testing. The rise in cost-effective ELISA test kits will lead to increased adoption in highly populated countries such as India, thereby expected to drive the growth of this segment.
In addition, in October 2020, Cipla Limited commercialized COVID-19 antibody detection kits in India. Under the technology transfer from the Indian Council of Medical Research, in collaboration with KARWA Ltd. (ICMR). Rising collaborations for the commercialization of the ELISA test are further expected to propel segment growth.
Therefore, rising product launches, a rise in collaborations, and a rise in the prevalence of cancers are expected to drive the growth of this segment over the forecast period.
North America has dominated the market with the largest revenue share. The factors that are likely to be responsible for the dominance of this segment are the rise in the prevalence of cardiovascular diseases, rising product launches, the presence of established players, technological advancements, and well-established healthcare infrastructure.
According to the Pan America Health Organization (PAHO), the prevalence of cardiovascular diseases in 2019 in the United States is 128 deaths per 100,000 population. The high prevalence of cardiovascular diseases in the United States will lead to increased adoption of CRP testing, thereby expected to drive the growth in this region.
In addition, according to the study published in Frontiers in Immunology, titled 'How C-Reactive Protein Structural Isoforms With Distinctive Bioactivities Affect Disease Progression' in September 2020, by the Roosevelt University College of Pharmacy, United States, because of the c-reactive protein (CRP) test functional bioactivity as the prototypic acute phase reactant has eluded clear definition for decades, diagnosticians of various conditions and diseases use CRP blood levels as a simple index for ongoing inflammation. Such studies will lead to further adoption of CRP testing for the diagnosis of inflammation in the body.
Furthermore, in October 2020, Nova Biomedical launched the Allegro C-reactive protein (CRP) test for its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. The Allegro and its StatStrip companion meter give 11 clinically necessary tests to assist clinicians in making therapeutic decisions and changes. The rising product launches for CRP testing in the United States will lead to increased adoption of these tests, thereby expected to drive the growth of this market in the United States.
Therefore, the rising prevalence of cardiovascular diseases, and rising product launches, among others, are the factors expected to drive the growth of this market in North America.
The C-reactive Protein Testing Market is fragmented and competitive. Factors such as strategic partnerships between key market players to expand their product portfolios, expansion in research and development, distribution, and management facilities to gain a competitive edge in the market are expected to drive the market growth. Some of the companies in this market include Abbott Laboratories, Danaher Corporation (Beckman Coulter Inc.), F. Hoffmann-La Roche AG, Merck KGaA, Quest Diagnostics, and Thermo Fisher Scientific Inc., among others.
This product will be delivered within 2 business days.
According to the study published in Annals of Clinical Microbiology and Antimicrobials, titled, 'Plasma CRP level is positively associated with the severity of COVID-19' in May 2020, plasma CRP levels were found to be linked to the severity of COVID-19 pneumonia. The findings could help distinguish mild COVID-19 pneumonia patients from those with moderate to severe COVID-19 pneumonia. This could serve as an early warning sign of serious disease, allowing doctors to better stratify patients for transfer to an intensive care unit. The importance of CRP testing in the COVID-19 infection for the stratification of patients will lead to increased demand for CRP testing, thereby impacting the market growth during the pandemic.
The major factors propelling the growth of the C-reactive protein testing market include the rise in prevalence of inflammatory disorders, diabetes, and cancers, the increasing global incidence of endometriosis in women, the rise in funding for the technological advancement in diagnostics, and the rise in the adoption of point-of-care devices.
According to the World Health Organization, cardiovascular diseases claimed the lives of 17.9 million individuals worldwide in 2019, accounting for 32% of all deaths. Heart attacks and strokes were responsible for 85 percent of these deaths. The rising prevalence of cardiovascular diseases will lead to increased adoption of CRP testing to identify the risk of cardiovascular disease, thereby expected to drive the market growth.
Furthermore, the rise in product launches of point-of-care CRP tests is expected to contribute to the growth of the CRP testing market. For instance, in May 2020, ProciseDx filed a 510k for the Procise CRP test. The test is performed utilizing ProciseDx's FRET (Fluorescent Resonance Energy Transfer) Point of Care equipment, which is an inflammatory marker extensively used in gastrointestinal therapy. This will lead to increased adoption of the point of care CRP test, thereby expected to drive the growth of the market.
Therefore, the rising prevalence of cardiovascular disease, and rising product launches for point-of-care CRP testing, among others, are expected to drive the growth of this market over the forecast period. On the other hand, lack of public awareness and availability of alternative treatments are the factors that are expected to hinder market growth.
Key Market Trends
Enzyme-linked Immunosorbent Assay (ELISA) Segment is Expected to Hold a Significant Share in the Market Over the Forecast Period
The Enzyme-linked Immunosorbent Assay (ELISA) segment is expected to hold a significant share in the C-reactive protein testing market. The factors such as rise in prevalence of cancers, rise in infections such as COVID-19, rise in partnership for the commercialization of ELISA tests, and rise in product launches, among others, are expected to drive the growth of this segment during the forecast period.
According to Globocan 2020, the global cancer burden has risen to 19.3 million cases and 10 million cancer deaths in 2020. As the ELISA test can be a useful technique for detecting cancer markers, there will be increased adoption of this test for the detection of cancer across the world, thereby expected to drive the growth of this segment.
Furthermore, rising product launches of ELISA testing kits are also expected to propel this segment growth. For instance, in June 2021, J Mitra and Co Pvt Ltd, an Indian Invitro Diagnostics company, released the Covid-19 Ag Microlisa Elisa Test kit, often known as the Elisa Antigen Test to fight against Covid-19 by reducing the overall cost of testing. The rise in cost-effective ELISA test kits will lead to increased adoption in highly populated countries such as India, thereby expected to drive the growth of this segment.
In addition, in October 2020, Cipla Limited commercialized COVID-19 antibody detection kits in India. Under the technology transfer from the Indian Council of Medical Research, in collaboration with KARWA Ltd. (ICMR). Rising collaborations for the commercialization of the ELISA test are further expected to propel segment growth.
Therefore, rising product launches, a rise in collaborations, and a rise in the prevalence of cancers are expected to drive the growth of this segment over the forecast period.
North America has Been Reported with the Largest Growth and is Expected to Follow the Same Trend Over the Forecast Period
North America has dominated the market with the largest revenue share. The factors that are likely to be responsible for the dominance of this segment are the rise in the prevalence of cardiovascular diseases, rising product launches, the presence of established players, technological advancements, and well-established healthcare infrastructure.
According to the Pan America Health Organization (PAHO), the prevalence of cardiovascular diseases in 2019 in the United States is 128 deaths per 100,000 population. The high prevalence of cardiovascular diseases in the United States will lead to increased adoption of CRP testing, thereby expected to drive the growth in this region.
In addition, according to the study published in Frontiers in Immunology, titled 'How C-Reactive Protein Structural Isoforms With Distinctive Bioactivities Affect Disease Progression' in September 2020, by the Roosevelt University College of Pharmacy, United States, because of the c-reactive protein (CRP) test functional bioactivity as the prototypic acute phase reactant has eluded clear definition for decades, diagnosticians of various conditions and diseases use CRP blood levels as a simple index for ongoing inflammation. Such studies will lead to further adoption of CRP testing for the diagnosis of inflammation in the body.
Furthermore, in October 2020, Nova Biomedical launched the Allegro C-reactive protein (CRP) test for its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. The Allegro and its StatStrip companion meter give 11 clinically necessary tests to assist clinicians in making therapeutic decisions and changes. The rising product launches for CRP testing in the United States will lead to increased adoption of these tests, thereby expected to drive the growth of this market in the United States.
Therefore, the rising prevalence of cardiovascular diseases, and rising product launches, among others, are the factors expected to drive the growth of this market in North America.
Competitive Landscape
The C-reactive Protein Testing Market is fragmented and competitive. Factors such as strategic partnerships between key market players to expand their product portfolios, expansion in research and development, distribution, and management facilities to gain a competitive edge in the market are expected to drive the market growth. Some of the companies in this market include Abbott Laboratories, Danaher Corporation (Beckman Coulter Inc.), F. Hoffmann-La Roche AG, Merck KGaA, Quest Diagnostics, and Thermo Fisher Scientific Inc., among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Zoetis (Abaxis Inc.)
- Abbott Laboratories
- Danaher Corporation (Beckman Coulter Inc.)
- F. Hoffmann-La Roche AG
- Laboratory Corporation of America Holdings
- Merck KGaA
- Quest Diagnostics
- Randox Laboratories Ltd
- Siemens Healthineers
- Thermo Fisher Scientific Inc.
- Getein Biotech, Inc.
- HORIBA, Ltd
- Boditech Med Inc.
- Aidian
Methodology
LOADING...
